{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T22:35:04Z","timestamp":1787438104346,"version":"build-2736575974"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","issue":"4","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["MIRNA"],"published-print":{"date-parts":[[2021,2,3]]},"abstract":"<jats:sec>\n<jats:title>Introduction:<\/jats:title>\n<jats:p>Prostate Cancer (PCa) is the second most common cancer in males and the\nfifth in cancer-associated mortality. Although the Prostate-Specific Antigen (PSA) test is widely used\nin PCa screenings, it has significant limitations in the differential diagnosis of PCa. Therefore, studies\non developing new biomarkers for PCa diagnosis are ongoing. MiRNAs are good candidate biomarkers\nfor the diagnosis of cancers, including prostate cancer, as they can be easily detected from\ncirculation.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p> In this study, it is aimed to determine the diagnostic value of serum levels of miR-223-3p\nand -223-5p in Benign Prostate Hyperplasia (BPH), Chronic Prostatitis (CP) and Prostate Cancer\n(PCa).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>Serum samples were collected from 68 patients in total (25 BPH, 10 CP, 33 PCa). MiR-223-\n3p and -223-5p levels were measured in serum with qRT-PCR. The Ct values of miRNAs were normalized\naccording to the Ct value of ce-miR-39 and calculated -\u0394Ct values were used for statistical\nanalyses.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>The serum levels of miR-223-3p and -223-5p were downregulated in the PCa and CP groups,\ncompared to the BPH group. There was no statistically significant difference between PCa and CP\ngroups. The sensitivity and specificity of miR-223-3p, -223-5p and their combination were calculated\nas 88% and 88%; 86% and 79%; 93% and 92% in discriminating BPH and PCa groups, respectively.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p> In this study, it was shown that miR-223-3p and -223-5p were both detectable in circulation.\nmiR-223-3p, -223-5p, and their combination may be good candidate biomarkers for prostate cancer\ndiagnosis. Also, observation of similar serum levels of miR-223-3p and -223-5p between CP and\nPCa groups suggests that miR-223 may play a role in prostate cancer development originated from\nchronic inflammation.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/2211536609666201106090458","type":"journal-article","created":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T14:45:21Z","timestamp":1604673921000},"page":"303-309","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Serum Levels of miR-223-3p and miR-223-5p in Prostate Diseases"],"prefix":"10.2174","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0695-5708","authenticated-orcid":true,"given":"Yakup","family":"D\u00fclgero\u011flu","sequence":"first","affiliation":[{"name":"Kulu State Hospital, Department of Medical Biochemistry, Kulu, Konya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onur","family":"Ero\u011flu","sequence":"additional","affiliation":[{"name":"Bilecik Seyh Edebali University, Faculty of Science and Letters, Department of Molecular Biology and Genetics, Bilecik, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","container-title":["MicroRNA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/187657","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/187657\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/187657","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T09:31:07Z","timestamp":1612776667000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/187657\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,3]]},"references-count":0,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,2,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/2211536609666201106090458","relation":{},"ISSN":["2211-5366"],"issn-type":[{"value":"2211-5366","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-02-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-24","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}